Cytokinetics, Incorporated (FRA:KK3A)

Germany flag Germany · Delayed Price · Currency is EUR
56.50
-1.00 (-1.74%)
Last updated: Dec 5, 2025, 8:04 AM CET
16.26%
Market Cap 6.90B
Revenue (ttm) 74.33M
Net Income (ttm) -640.88M
Shares Out n/a
EPS (ttm) -5.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 34
Open 56.50
Previous Close 57.50
Day's Range 56.50 - 56.50
52-Week Range 26.20 - 63.00
Beta n/a
RSI 57.03
Earnings Date Feb 27, 2026

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle tropo... [Read more]

Industry Pharmaceutical Preparations
Founded 1997
Employees 498
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol KK3A
Full Company Profile

Financial Performance

In 2024, Cytokinetics's revenue was $18.47 million, an increase of 145.34% compared to the previous year's $7.53 million. Losses were -$589.53 million, 12.0% more than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.